13666-71-2 Usage
Uses
Used in Pharmaceutical Industry:
2-AMINO-N-(3-MORPHOLIN-4-YLPROPYL)BENZAMIDE is used as a chemical intermediate for the development of new pharmaceuticals due to its structural features that allow for versatile chemical modifications and potential interactions with biological targets.
Used in Research and Development:
In the field of scientific research, 2-AMINO-N-(3-MORPHOLIN-4-YLPROPYL)BENZAMIDE serves as a valuable compound for exploring its interactions with biological systems, potentially leading to the discovery of new therapeutic agents or mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 13666-71-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,6,6 and 6 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 13666-71:
(7*1)+(6*3)+(5*6)+(4*6)+(3*6)+(2*7)+(1*1)=112
112 % 10 = 2
So 13666-71-2 is a valid CAS Registry Number.
InChI:InChI=1/C14H21N3O2/c15-13-5-2-1-4-12(13)14(18)16-6-3-7-17-8-10-19-11-9-17/h1-2,4-5H,3,6-11,15H2,(H,16,18)
13666-71-2Relevant academic research and scientific papers
Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase
Li, Yang,Ganesh, Thota,Diebold, Becky A,Zhu, Yerun,McCoy, James W,Smith, Susan M. E,Sun, Aiming,Lambeth, J. David
supporting information, p. 1047 - 1052 (2015/10/20)
Myeloperoxidase (MPO) is a key antimicrobial enzyme, playing a normal role in host defense, but also contributing to inflammatory conditions including neuroinflammatory diseases such as Parkinsons and Alzheimers. We synthesized and characterized more than 50 quinazolin-4(1H)-one derivatives and showed that this class of compounds inhibits MPO with IC50 values as low as 100 nM. Representative compounds showed partially reversible inhibition that was competitive with respect to Amplex Red substrate and did not result in the accumulation of MPO Compound II. Members of this group show promise for therapeutic development for the treatment of diseases in which inflammation plays a pathogenic role.
